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Bats are natural reservoirs for the majority of lyssaviruses globally, and are unique among
mammals in having exceptional sociality and longevity. Given these facets, and the recognized
status of bats as reservoirs for rabies viruses (RABVs) in the Americas, individual bats may
experience repeated exposure to RABV during their lifetime. Nevertheless, little information exists
with regard to within-host infection dynamics and the role of immunological memory that may
result from abortive RABV infection in bats. In this study, a cohort of big brown bats (Eptesicus
fuscus) was infected intramuscularly in the left and right masseter muscles with varying doses
[10
”0.1–10
4.9 median mouse intracerebral lethal doses (MICLD50)] of an E. fuscus RABV variant
isolated from a naturally infected big brown bat. Surviving bats were infected a second time at
175 days post-(primary) infection with a dose (10
3.9–10
4.9 MICLD50) of the same RABV variant.
Surviving bats were infected a third time at either 175 or 305 days post-(secondary) infection
with a dose (10
4.9 MICLD50) of the same RABV variant. When correcting for dose, similar
mortality was observed following primary and secondary infection, but reduced mortality was
observed following the third and last RABV challenge, despite infection with a high viral dose.
Inducible RABV-neutralizing antibody titres post-infection were ephemeral among infected
individuals, and dropped below levels of detection in several bats between subsequent infections.
These results suggest that long-term repeated infection of bats may confer significant
immunological memory and reduced susceptibility to RABV infection.
INTRODUCTION
Rabies is an acute, progressive encephalitis caused by single-
stranded, negative-sense RNA viruses in the genus Lyssavirus.
Rabies virus (RABV) has the broadest host range among
lyssaviruses. Rabies has a case fatality ratio approaching
100%, one of the highest of any infectious disease, although
it is preventable by appropriate pre- and post-exposure
prophylaxis. Bats are the primary reservoirs for 10 of 11
recognized lyssaviruses. Among bats, the distribution of
RABV is limited to New World fauna, although sylvatic or
domestic cycles occur in carnivores globally. In North
America (NA), RABV variants tend to be species-associated
among various bat and mesocarnivore taxa, indicating that
intraspecific contact is the predominant mode of transmis-
sion and maintenance between animals (Smith, 1996).
However, spillover infections from wildlife occur to humans,
domestic animals and other sylvatic hosts (McQuiston
et al., 2001; Messenger et al., 2002, 2003).
Big brown bats (Eptesicus fuscus) are one of the most widely
distributed species of bat in NA, with a geographical range
that extends from the southern provinces of Canada into
northern South America (Hall, 1981; Koopman, 1982). Big
brown bats utilize a variety of different roost structures,
including natural and man-made roosts. This species is
gregarious, typically roosting in colonies of 25–75 indivi-
duals, and may undergo short-distance migrations between
summer maternity colonies and winter hibernacula (Kurta
& Baker, 1990). Consistent with their synanthropic
roosting ecology, big brown bats rank highest annually in
the number of bats submitted for rabies diagnosis in the
USA (Mondul et al., 2003). Although RABV from E. fuscus
has been implicated only in a single indigenous human
rabies case (Blanton et al., 2009; Messenger et al., 2002),
and spillover into domestic animals implicated only rarely
(McQuiston et al., 2001), spillover infections in wildlife are
more common (Messenger et al., 2003). Furthermore,
recent surveillance suggests repeated spillover and a host
shift of RABV from E. fuscus into striped skunks (Mephitis
mephitis) and grey foxes (Urocyon cinereoargenteus), which
has led to an epizootic of rabies in Flagstaff, AZ, USA
(Blanton et al., 2009; Leslie et al., 2006).
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RABV among natural colonies of big brown bats. Such
investigations demonstrate collectively that exposure is
temporally and geographically enzootic in natural colonies.
Early studies found RABV infection prevalence ranging
from 0 to 3% among natural colonies of big brown bats in
New England (Daniels et al., 1960; Girard et al., 1965). In a
later study from New York, seven colonies were surveyed
and 3% (eight of 278) of big brown bats were diagnosed
with RABV infection, whereas RABV-neutralizing antibod-
ies (rabies VNA) were detected in 10% of bats (Trimarchi
& Debbie, 1977). Concurrent studies in Canada reported
RABV infection prevalence of 1–6% among natural
colonies of big brown bats in Alberta (Pybus, 1986;
Schowalter, 1980). Additionally, a 3 year study of over 20
colonies of big brown bats around Fort Collins, CO, USA,
found rabies VNA seroprevalence ranging from 3 to 35%
among colonies, and was one of the first studies to
demonstrate multi-year maintenance of rabies VNA in
individual bats (O’Shea et al., 2003). Most recently, a
3 year study of 10 colonies of big brown bats in New
Hampshire and Massachusetts detected rabies VNA
seroprevalence in 2–17% of bats across years (Moore
et al., 2008). Although evidence of RABV infection is
widespread, RABV variants circulating in big brown
bat populations in NA appear to be structured geograph-
ically (Messenger et al., 2003; Smith, 1996), suggest-
ing a complex epizootiology that is consistent with the
population genetic structure of this host (Turmelle, 2002).
The longevity, philopatry and gregarity of certain bats are
exceptional among mammals (Austad & Fischer, 1991;
Kunz & Pierson, 1994). Two long-term banding studies
demonstrated that big brown bats can survive in the wild
for up to 20 years (Goehring, 1972; Hitchcock, 1965).
Given such high contact rates, exceptional longevity and
evidence of regular exposure to RABV in natural colonies,
big brown bats may be subject to repeated infection with
RABV in the wild. However, no experimental studies have
examined the effects of multiple exposures and the
potential role of immunological memory to RABV
infection. The objectives of this study were to determine
whether abortive RABV infections confer immunity against
subsequent challenge, and to evaluate the induction of
rabies VNA in the anamnestic response to RABV infection
in big brown bats.
RESULTS
A cohort of bats was used in three RABV infection studies
(Table 1). RABV sequences from brain-tissue samples for a
subset of bats that were diagnosed with rabies during the
study (n514; incubation period range, 13–140 days)
demonstrated 100% sequence identity with the experi-
mental inoculum. Cumulative survivorship of bats in the
primary, secondary and tertiary infections is shown in
Fig. 1.
Primary infection
Two bats were censored due to non-specific mortality
during the primary RABV infection [days 12 and 113 post-
infection (p.i.)]. There was 40% (17 of 43) mortality
among the remaining bats, with demonstrable RABV
antigen in the central nervous system (CNS), summarized
across all RABV doses (Table 2). Dose effects on mortality
to infection were not statistically significant (n543; df55,
37; x
255.9; P50.32). Among infected bats, 35% (15 of 43)
seroconverted. Among the 17 bats that succumbed to
RABV infection, only 6% (one of 17) seroconverted, and
rabies VNA in the single bat was only observed upon the
day of terminal infection (day 22 p.i.). A statistically
significant difference was found in the probability of
seroconversion when comparing survivors with bats that
succumbed to RABV infection (54 versus 6%, respectively;
n543; df51, 41; x
2512.1; P,0.001). With few exceptions,
maximum rabies VNA titres were observed between 31 and
42 days p.i. Substantial variation was recorded in the
incubation periods of bats that succumbed to RABV
infection (n517; median, 19 days; range, 13–140 days).
Higher RABV inoculation doses were correlated with
shorter incubation periods in animals that succumbed
(n517; Spearman’s r, 20.52; P50.03).
Table 1. Details of experimental RABV infection of bats
Days of blood sampling for VNA determination
Primary infections
24 January 2007 0, 10, 17, 31, 42, 57, 93, 104, 118, 133, 147, 174 (n525; one bat censored)
26 April 2007 0, 7, 13, 22, 29, 41, 55, 68, 83, 98, 145 (n520; one bat censored)
Secondary infections
18 July 2007 (day 175 p.i.) 0, 5, 14, 27, 43, 98, 147 (n517; none censored)
18 October 2007 (day 175 p.i.) 0, 15, 27, 41, 54, 89, 133, 160 (n59; one bat censored)
Tertiary infections
8 January 2008 (day 174 p.i.) 0, 20, 48, 120 (n510; none censored)
18 August 2008 (day 305 p.i.) 0, 29, 86, 149 (n56; none censored)
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Despite routine seroconversion during the primary infec-
tion, 88% (23 of 26) of bats were seronegative prior to the
secondary infection (Table 2). One animal was censored
during the secondary infection (bat 68, day 89 p.i.).
Mortality to the secondary infection (36%, nine of 25 bats)
was not statistically significantly lower than that observed in
the primary infection (P50.49). During the secondary
infection, 60% (15 of 25) of bats seroconverted. Among the
nine bats that succumbed to RABV infection, 33%
seroconverted (three of nine). The titres for these three bats
were respectively observed 5 days prior to death (21 days
incubation), 6 days prior to death (19 days incubation) and
upon the day of death (19 days incubation). A statistically
significant difference was found in the probability of
seroconversion when comparing survivors with bats that
succumbed (75 versus 33%, respectively; n525; df51, 23;
x
254.2; P50.04). The incubation periods of animals that
succumbed ranged from 14 to 27 days (median, 19 days).
Tertiary infection
For the cohort of bats observed for 174 days post-
secondary infection (i.e. 349 days post-primary infection),
60% (six of 10) had a positive rabies VNA titre
immediately prior to the start of the tertiary infection
(Table 1). For the cohort of bats observed for 305 days
post-secondary infection (i.e. 480 days post-primary infec-
tion), none (of six) was seropositive immediately prior to
the start of the tertiary infection. One animal succumbed
during the tertiary infection with an incubation period
of 22 days, but the maximum rabies VNA titre and
seroconversion status were not determined. Mortality
following tertiary exposure was significantly lower (6%,
one of 16 bats) compared with mortality following primary
(Fisher’s exact test, P50.01) and secondary (Fisher’s exact
test, P50.03) RABV infections. During the tertiary
infection period, 27% (four of 15) of surviving bats
demonstrated apparent seroconversion.
DISCUSSION
Despite ample evidence that bats are reservoirs of several
emerging viral zoonoses and that several taxa have
exceptional sociality and longevity, there have been no
studies that have examined the response to repeated virus
infection in bats. The immunological response to peri-
pheral RABV infection includes both innate and adaptive
immune components and signalling molecules (Lafon,
2007). Helper and cytotoxic T cells are activated to
recognize and clear virus particles respectively outside
and inside infected cells, which presumably primes both
cell types for any subsequent response to infection (i.e.
anamnestic response). However, once the virus gains access
to the CNS, the host adaptive immune response may be
severely limited (Lafon, 2007). Pathogenic variants of
RABV tend to invade the CNS and cause an acute,
progressive infection, whereas less virulent viruses may
have limited invasion of the CNS and cause abortive
infection (Dietzschold et al., 2008; Wang et al., 2005).
However, studies have demonstrated that RABV patho-
genicity correlates inversely with the rate of viral RNA
synthesis, production of viral glycoprotein and assembly of
infectious particles, which may result in limited host
immune detection and response (Dietzschold et al., 2008).
Regardless of RABV pathogenicity, similar host adaptive
immune responses are triggered in the periphery during
initial time periods p.i. More pathogenic viruses may
impair or evade the host immune response during later
periods p.i. (Lafon, 2007). Furthermore, the effect of
inoculum dose on pathogenicity is complex, considering
that low doses of RABV may not establish a productive
peripheral infection, whereas high doses of RABV may
evade or overwhelm the host peripheral immune response
and rapidly invade the CNS.
The results of this study support previous suggestions that
high doses of pathogenic RABV lead to more rapid CNS
invasion (Baer & Bales, 1967). For example, a significant
negative correlation was observed between inoculum dose
and incubation period in the primary infection of bats.
Baer & Bales (1967) suggested that longer incubation
periods lead to the development of higher viral titres in the
CNS and salivary glands upon clinical presentation in
Brazilian free-tailed bats (Tadarida brasiliensis). Although
titration of virus in brains and salivary glands from
clinically rabid bats was not conducted in the present
study, a possible negative-feedback link between dose,
incubation period and virus shedding of clinically infected
bats warrants additional investigation.
Significant differences were observed in the seroconversion
probabilities of survivors versus bats that developed clinical
illness among cohorts of naı ¨ve (i.e. primary infection) and
Fig. 1. Cumulative survivorship of bats in the primary infection (solid
line, &), secondary infection (dashed line; m) and tertiary infection
(dotted line; $). Survivorship of bats in the primary infection from
higher doses only (10
3.9–10
4.9 MICLD50)i sa l s os h o w n( %).
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bats. These results do support a role of rabies VNA in the
successful clearance of a peripheral RABV infection, as
higher seroconversion probabilities were consistently
observed among surviving bats. Nevertheless, many bats
that did not seroconvert also survived RABV infection,
Table 2. Bat response to RABV infection
Bat
ID*
Primary infection Secondary infection Tertiary infection
DoseD Incubation
period (days)
Base
VNAd
Max.
VNAd
DoseD Incubation
period (days)
Base
VNAd
Max.
VNAd
DoseD Incubation
period (days)
Base
VNAd
Max.
VNAd
487 20.1 135 ,0.02 ,0.02
486 20.1 ,0.02 0.02 4.9 19 ,0.02 5.22
488 20.1 0.02 0.02 4.9 ,0.02 0.08 4.9 0.03 0.02
491 20.1 ,0.02 ,0.02 4.9 21 ,0.02 ,0.02
492 20.1 ,0.02 0.02 4.9 ,0.02 0.02 4.9 ,0.02 0.02
464 0.9 ,0.02 0.10 4.9 19 ,0.02 ,0.02
484 0.9 ,0.02 0.15 4.9 ,0.02 0.52 4.9 0.17 ,0.02
485 0.9 0.05 0.05 4.9 ,0.02 0.17 4.9 0.16 0.17
1892 0.9 ,0.02 0.83 4.9 0.17 0.49 4.9 0.27 0.39
462 1.9 32 ,0.02 ,0.02
1862 1.9 38 ,0.02 ,0.02
460 1.9 ,0.02 0.05 4.9 27 ,0.02 ,0.02
461 1.9 0.02 0.83 4.9 ,0.02 0.03 4.9 ,0.02 0.02
494 1.9 ,0.02 0.07 4.9 19 ,0.02 ,0.02
84 1.9 13 0.04 0.13
82 1.9 19 ,0.02 ,0.02
95 1.9 140 ,0.02 ,0.02
83 1.9 ,0.02 ,0.02 3.9 0.02 0.10 4.9 ,0.02 ,0.02
79 1.9 ,0.02 0.02 3.9 21 ,0.02 0.19
1883 2.9 15 ,0.02 ,0.02
454 2.9 26 ,0.02 0.02
455 2.9 26 ,0.02 0.02
456 2.9 ,0.02 1.66 4.9 14 ,0.02 0.02
457 2.9 ,0.02 0.41 4.9 23 ,0.02 ,0.02
87 2.9 15 ,0.02 ,0.02
96 2.9 22 ,0.02 0.19
88 2.9 ,0.02 0.09 3.9 ,0.02 0.16 4.9 0.03 0.03
89 2.9 ,0.02 0.21 3.9 ,0.02 0.29 4.9 ,0.02 ,0.02
90 2.9 ,0.02 0.02 3.9 19 ,0.02 1.26
497 3.9 27 0.02 0.02
440 3.9 ,0.02 0.16 4.9 0.09 1.33 4.9 0.30 0.29
442 3.9 ,0.02 1.66 4.9 0.07 .9.39 4.9 0.21 .9.39
498 3.9 ,0.02 0.05 4.9 ,0.02 0.24 4.9 0.07 0.06
1881 3.9 ,0.02 0.10 4.9 ,0.02 0.06 4.9 0.06 ,0.02
74 3.9 17 ,0.02 ,0.02
76 3.9 18 ,0.02 0.02
77 3.9 19 ,0.02 ,0.02
78 3.9 ,0.02 0.02 3.9 ,0.02 0.11 4.9 ,0.02 0.02
71 4.9 13 ,0.02 ,0.02
490 4.9 16 ,0.02 ,0.02
467 4.9 ,0.02 0.08 3.9 0.02 0.29 4.9 0.03 0.29
63 4.9 0.02 0.03 3.9 ,0.02 0.21 4.9 22 ,0.02
68§ 4.9 ,0.02 0.16 3.9 ,0.02 0.09
*Includes all non-censored bats during primary infection.
DDose expressed in units of log10(MICLD50).
dRabies VNA expressed in units of IU ml
21.
§Bat that was censored during the secondary infection.
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may contribute to RABV clearance. Furthermore, bats may
have had prior natural exposure to RABV before captivity,
despite being rabies VNA-seronegative at the start of the
study, which would obscure the interpretation of response
to primary RABV infection. Complex interactions occur
between natural individual variation in the immune
response among wild bats that allows RABV to replicate
differentially in the periphery and invade the CNS, and
obvious variation in RABV pathogenicity that leads to
subversion of the host immune response (Dietzschold et
al., 2008; Smith, 1981; Smith et al., 1982; Wang et al.,
2005).
Immunological memory does appear to be conferred to
bats following abortive infection. Rather, the results of this
study suggest that a single exposure may not protect bats
significantly against subsequent infections. If primary
infection doses had been uniformly higher [e.g. .10
3.9
median mouse intracerebral lethal doses (MICLD50)], then
immune-system priming and anamnestic response may
have been more apparent in the secondary infections.
Uneven sampling precluded more robust testing for a
relationship between primary virus inoculum dose and the
degree of immune-system priming between the primary
and secondary infections. The relationship between dose
and strength of priming using street RABVs is not well-
characterized in bats or other wildlife. Mortality was not
reduced significantly until the third infection, despite a low
proportion of bats that seroconverted. Thus, these results
suggest a reduced role of rabies VNA in the clearance of
RABV infection in bats that have experienced multiple
exposures. Development of specific markers to measure
other factors associated with immune responses, particu-
larly interferon and cytotoxic T-cell activity, is needed for a
more thorough characterization of immune response and
memory to virus infection in bats.
Data from field studies suggest that rabies VNA titres in
recaptured big brown bats fluctuate through time,
indicating repeated RABV exposure in natural colonies
(O’Shea et al., 2003). In the current study, a proportion of
bats responded to primary experimental RABV infection by
development of rabies VNA, although levels dropped below
the limit of detection (i.e. ,0.02 IU ml
21) by 6 months
p.i., which is consistent with previous studies (Jackson et
al., 2008). Following secondary infection, rabies VNA
persisted longer in infected bats that seroconverted, lasting
beyond 6 months but less than 1 year p.i., before levels
dropped below the limit of detection. However, repeated
observations of bats that did not develop a rabies VNA
response to experimental infection in this study provide
evidence that field serology may be limited for inference to
past exposure history of seronegative bats. Although
studies tend to report only seroprevalence (i.e. proportions
of seropositive individuals), rabies VNA titres of bats in
natural colonies are generally low, although a few bats may
have high titres (e.g. .2I Um l
21) (Turmelle et al., 2010).
The results of the current study suggest that bats with high
rabies VNA titres may have experienced repeated RABV
exposure, as few bats responded with high rabies VNA
titres to experimental RABV infection.
The observation of limited rabies VNA titres or the absence
of apparent seroconversion in response to experimental
infection with high doses of RABV is consistent with the
concept that pathogenic RABV may limit replication rate
and produce few infectious particles, thereby evading or
minimally activating host responses in the periphery
(Dietzschold et al., 2008). In the primary infection, bats
487 and 95 were infected with low doses of RABV and
exhibited incubation periods of 135 and 140 days,
respectively, but neither bat demonstrated a rabies VNA
response at any time p.i. Thus, RABV is clearly able to
evade successful immune recognition or response, perhaps
through periods of quiescence or via extremely low levels of
virus replication. Additional studies targeting variation in
virus pathogenicity and peripheral immune recognition
and activation may improve our understanding of street
RABV persistence in wildlife reservoirs, particularly in
long-lived social hosts such as bats, as several species are
capable of maintaining long-term enzootic transmission
despite fluctuating rabies VNA seroprevalence in natural
colonies. Such approaches to elucidation of pathogen
maintenance and within-host dynamics offer a fresh
perspective to emerging infectious diseases of bats and
other species (Dimitrov & Hallam, 2009).
METHODS
Animal collection and care. Experimental procedures and animal
care were performed in compliance with the CDC Institutional
Animal Care and Use Committee guidelines. Forty-five adult big
brown bats were captured from building roosts in Georgia (GA
permit #29-WSF-05-14). All bats were aged on the basis of the degree
of closure of the phalangeal epiphyses (Brunet-Rossinni & Wilkinson,
2009). Bats were held captive in quarantine for at least 1 month prior
to use, and marked individually with metal bands on the forearm.
Samples of baseline sera for rabies VNA and oral swabs for RABV
RNA were negative, which was used in assigning a presumptive naı ¨ve
status of all bats at the start of the experiment. After quarantine, bats
were separated randomly into cage groups of four or five individuals
each, allowing an even distribution of males and females when
possible. Each group was housed in a separate 81363056254 mm
stainless steel cage, with all cages held collectively in a room at 24–
27 uC and 30% humidity.
Experimental infections. The overall infection and sampling
scheme is listed in Table 1. The RABV used for these experiments
was collected from the salivary glands of a naturally infected big
brown bat in Pennsylvania during 2006 (CDC A06-3684). This virus
was passaged once through murine neuroblastoma cell culture. On
day 0, all 45 bats were inoculated intramuscularly (i.m.) into both the
left and right masseter muscles with varying doses of RABV (10
20.1–
10
4.9 MICLD50; Table 2) in 0.05 ml. Bats were observed for 175 days
p.i. Twenty-six bats that survived the initial infection were reinfected
on day 175 p.i. with 10
3.9 or 10
4.9 MICLD50 of the same RABV
variant in 0.05 ml. Bats in the second experiment were observed for
either 174 or 305 days p.i. On day 174 or 305 post-secondary
infection (i.e. day 349 or 480 post-primary infection), 16 surviving
bats were infected a third time with 10
4.9 MICLD50 of the same RABV
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140 days p.i., for a combined observation period of 489–620 days for
all bats.
Blood samples were obtained routinely from a peripheral wing vein
during each experiment (Table 1) or by the intracardiac route for
terminal exsanguination at euthanasia (Voigt & Cruz-Neto, 2009),
and collected in sterile heparinized microcapillary tubes. Plasma was
separated by low-speed centrifugation (2200 g) and stored at 220 uC
until processing. Bats were euthanized, by exsanguination under
anaesthesia followed by intracardiac injection of a barbiturate
solution (i.e. pentobarbital sodium and phenytoin sodium), upon
presentation of two or more definitive clinical signs of RABV
infection (e.g. increased aggression/reclusion, acute weight loss,
ataxia, atypical vocalizations, paresis or paralysis). Brain tissue was
collected and tested for RABV antigen by the direct fluorescent
antibody (DFA) test, as described by Dean et al. (1996), using a
fluorescein isothiocyanate-labelled monoclonal antibody conjugate
(Fujirebio Diagnostics, Inc.). For a subset of DFA-positive bats, total
RNA was extracted from the brain tissue of individual bats and the
RABV nucleoprotein gene was amplified and sequenced as described
by Trimarchi & Smith (2002).
Detection of rabies VNA. A modified rapid fluorescent focus
inhibition test (Jackson et al., 2008; Smith et al., 1996), using RABV
challenge virus standard (CVS-11, V399), was used to assay rabies
VNA in the blood plasma of individual bats. The rabies VNA end-
point titres of individual bats were calculated by the method of Reed
& Muench (1938) and were converted to IU ml
21 by comparison
with the US Standard Rabies Immune Globulin (SRIG; Laboratory of
Standards and Testing, Food and Drug Administration, USA) diluted
to 2 IU ml
21. Any values .0.06 IU ml
21, equivalent to .50%
reduction of 50 focus-forming doses at a 1:13 dilution in this study,
were considered as evidence of neutralization according to prior
routine assay criteria (Smith et al., 1996). Maximum rabies VNA titres
during the course of each infection are reported for individual bats.
Titres that both were positive and exhibited a fourfold or greater
increase above baseline values of the primary infection were
considered evidence of seroconversion p.i.
Statistical analyses. All statistics were performed using JMP v.7
(SAS Institute). All bats that were censored due to non-specific deaths
were excluded from the statistical calculations, including two bats
during the primary infection and one bat during the secondary
infection. A nominal logistic regression model was used to test for
effects of categorical variables on infection or seroconversion
outcomes using the likelihood ratio test statistic (a50.05).
Spearman’s rank order correlation tested for a non-parametric
correlation between incubation period and inoculum dose. Fisher’s
exact one-tailed test was used to test the hypothesis that mortality in a
subsequent infection was lower than in the previous infection
(a50.05).
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